Comparison of long-term clinical results of double versus single internal mammary artery bypass grafting.

BACKGROUND: The long-term benefits of double versus single internal mammary artery (IMA) coronary bypass grafting have not yet been established. METHODS: Six hundred patients were studied retrospectively 10 years after coronary revascularization using saphenous vein grafts (SVGs) only or single or double IMA grafts. RESULTS: Patients with double IMA grafts were younger and were more likely to have diabetes, left main coronary stenosis, and three-vessel coronary artery disease than patients with SVGs or single IMA grafts. Patients with SVGs and double IMA grafts had a greater number of diseased coronary vessels and a greater number of coronary bypass grafts per patient than patients with single IMA grafts (mean +/- SEM, 2.8 +/- 1.0, 2.8 +/- 0.7, 2.1 +/- 0.8 grafts per patient, respectively, p < 0.0001). Actuarial survival rates 10 years after placement of SVGs and single and double IMA grafts averaged 83% +/- 6%, 90% +/- 4%, and 87% +/- 8%, respectively (p = 0.03). Cox regression analysis showed that diabetes (relative risk, 2.03; 95% confidence interval, 1.55 to 2.66) and chronic pulmonary obstructive disease (relative risk, 2.20; 95% confidence interval, 1.58 to 3.80) increased, whereas an IMA graft on the left anterior descending coronary artery significantly decreased, the risk of death after operation (relative risk, 0.45; 95% confidence interval, 0.36 to 0.57) throughout the follow-up period. CONCLUSIONS: Use of an IMA graft on the left anterior descending coronary artery improves survival compared with use of an SVG. Although patients with double IMA grafts had a greater number of poor prognosis risk factors before operation, their 10-year survival rate was similar to that of patients with a single IMA graft.

Coronary endarterectomy revisited: mid-term angiographic results.

OBJECTIVES: To evaluate the value of concomitant coronary endarterectomy (CE) in the modern era of coronary revascularization. METHODS: Retrospective study. Twenty-eight patients (five women; 23 men) who underwent coronary endarterectomy were angiographically studied 24 +/- 22 months after the procedure. Necessity CE (vessel completely occluded or with lumen less than 1 mm) was performed on the left anterior descending (LAD) artery in 12 patients, the right coronary artery (RCA) in nine, the obtuse marginal artery (OM) in five and a diagonal branch in two patients. Conduits used for revascularization were the internal thoracic artery (ITA) in 11 (all anastomosed to the LAD; combined with saphenous vein patch in four) and a saphenous vein graft in 17 patients. Mean atherosclerotic core length was 3.3 +/- 1.8 cm. An average of 3.1 +/- 0.7 distal anastomoses per patient were constructed, with mean aortic cross-clamp and cardiopulmonary bypass times of 61.2 +/- 20.2 mins and 94.0 +/- 23.5 mins, respectively. RESULTS: Overall, angiographic patency rate was 71% (20 of 28) for the endarterectomized vessels (12 of 12 LAD, six of nine RCA, two of five OM and none of two diagonal arteries) and 93% (57 of 61) for the nonendarterectomized vessels. Among the eight patients with occluded CE vessels, two sustained a perioperative myocardial infarction, five developed angina during follow-up, and one patient remained asymptomatic. CONCLUSION: Necessity CE demonstrates acceptable mid-term patency. In addition, this study showed excellent patency following CE of the LAD revascularized with the ITA, with or without only a saphenous vein patch.

[Tricuspid valve replacement: long-term clinical and echocardiographic follow-up]. / Le remplacement valvulaire tricuspidien: suivi clinique et échographique à long terme.

Long term results of tricuspid valve replacement, were evaluated by echocardiographic and clinical means retrospectively on 55 patients hospitalized at the Montreal Heart Institute between 1969 and 1993. Twenty seven percent were male and 73% female. Taking into account differences in means of myocardial protection the whole population was divided in 2 groups. Group 1: 19 patients from 1969 to 1980. Group 2: 36 patients - from 1981 to 1994. Forty seven patients (85%) received a bioprosthesis and 8 (15%) a mechanical valve. Forty one (74%) had another surgical procedure and 60% (33 patients) were re-operations. Mortality at 30 days is 23% (13 patients) -15% group 1 and 27% group 2. Twenty six patients (72%) of group 2 were re-operations compared with 7 (36%) for group 1 (p = 0.026). Risk factors of operative mortality were: high systolic pulmonary pressure (0.051), bypass time (0.012) and abnormal ejection fraction (0.025). Mean time of follow up is 113.8 months completed at 95%. Six patients were re-operated; 4 for failure of bioprosthesis 11.5 years (mean) after initial surgery. Forty three percent of patients presented with an amelioration of NYHA class. 26% in class I and 50% in class II. Mean gradient across the tricuspid valve was 4.1 +/- 1 mm Hg. Twenty two over 42 patients (50%) died during follow up: 75 months after surgery.

[Effect of ranitidine on blood alcohol and glucose levels after ingestion of alcohol]. / Effet de la ranitidine sur l'alcoolémie et la glycémie après ingestion d'alcool.

Are alcohol and glucose blood levels modified in fasting subjects taking ranitidine? This experience tries to simulate normal life conditions. Nine men, volunteer, aged from 24 to 29 years old, without any digestive symptoms, ate a standard lunch after five hours of fasting, took 0.35 g of alcohol per kg. Ethanol blood levels, glycemia and blood levels of insulin and glucagon were taken at regular intervals every 10 to 15 minutes during all the experiment (120 minutes). After the initial experiment, all subjects took 150 mg of ranitidine p.o. b.i.d. during seven days. Afterward they were submitted to the same protocol. Between both experiments no differences were found on blood levels of ethanol. Peak concentration, decreasing rate, and biodisponibility (estimated by area under the curve) did not change. There was a tendency to have a faster decrease in glucose blood level (p < 0.05). This study does not show any significant modification of ethanol metabolism after taking ranitidine p.o.; those results are differing from data already found with studies using cimetidine.